Literature DB >> 21851094

Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors.

Jason C Morris1, Johanna Chiche, Caroline Grellier, Marie Lopez, Laurent F Bornaghi, Alfonso Maresca, Claudiu T Supuran, Jacques Pouysségur, Sally-Ann Poulsen.   

Abstract

Carbonic anhydrase (CA) enzymes, specifically membrane-bound isozymes CA IX and CA XII, underpin a pH-regulating system that enables hypoxic tumor cell survival and proliferation. CA IX and XII are implicated as potential targets for the development of new hypoxic cancer therapies. To date, only a few small molecules have been characterized in CA-relevant cell and animal model systems. In this paper, we describe the development of a new class of carbohydrate-based small molecule CA inhibitors, many of which inhibit CA IX and XII within a narrow range of low nanomolar K(i) values (5.3-11.2 nM). We evaluate for the first time carbohydrate-based CA inhibitors in cell-based models that emulate the protective role of CA IX in an acidic tumor microenvironment. Our findings identified two inhibitors (compounds 5 and 17) that block CA IX-induced survival and have potential for development as in vivo cancer cell selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21851094     DOI: 10.1021/jm200892s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

1.  Essential role of carbonic anhydrase XII in secretory gland fluid and HCO3 (-) secretion revealed by disease causing human mutation.

Authors:  Jeong Hee Hong; Emad Muhammad; Changyu Zheng; Eli Hershkovitz; Soliman Alkrinawi; Neta Loewenthal; Ruti Parvari; Shmuel Muallem
Journal:  J Physiol       Date:  2015-12-07       Impact factor: 5.182

2.  Carbonic Anhydrase Inhibition with Benzenesulfonamides and Tetrafluorobenzenesulfonamides Obtained via Click Chemistry.

Authors:  Nicolino Pala; Laura Micheletto; Mario Sechi; Mayank Aggarwal; Fabrizio Carta; Robert McKenna; Claudiu T Supuran
Journal:  ACS Med Chem Lett       Date:  2014-06-07       Impact factor: 4.345

3.  1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.

Authors:  Claudia Ferroni; Antonella Pepe; Yeong Sang Kim; Sunmin Lee; Andrea Guerrini; Marco Daniele Parenti; Anna Tesei; Alice Zamagni; Michela Cortesi; Nadia Zaffaroni; Michelandrea De Cesare; Giovanni Luca Beretta; Jane B Trepel; Sanjay V Malhotra; Greta Varchi
Journal:  J Med Chem       Date:  2017-03-20       Impact factor: 7.446

4.  Systemic buffers inhibit carcinogenesis in TRAMP mice.

Authors:  Arig Ibrahim-Hashim; Heather H Cornnell; Dominique Abrahams; Mark Lloyd; Marilyn Bui; Robert J Gillies; Robert A Gatenby
Journal:  J Urol       Date:  2012-06-15       Impact factor: 7.450

Review 5.  Metformin--mode of action and clinical implications for diabetes and cancer.

Authors:  Ida Pernicova; Márta Korbonits
Journal:  Nat Rev Endocrinol       Date:  2014-01-07       Impact factor: 43.330

Review 6.  Links between metabolism and cancer.

Authors:  Chi V Dang
Journal:  Genes Dev       Date:  2012-05-01       Impact factor: 11.361

7.  Advances in Anti-Cancer Drug Development Targeting Carbonic Anhydrase IX and XII.

Authors:  Mam Y Mboge; Robert McKenna; Susan C Frost
Journal:  Top Anticancer Res       Date:  2015

Review 8.  Disrupting proton dynamics and energy metabolism for cancer therapy.

Authors:  Scott K Parks; Johanna Chiche; Jacques Pouysségur
Journal:  Nat Rev Cancer       Date:  2013-09       Impact factor: 60.716

9.  The Carbonic Anhydrase Inhibitor E7070 Sensitizes Glioblastoma Cells to Radio- and Chemotherapy and Reduces Tumor Growth.

Authors:  Silvia A Teixeira; Mariano S Viapiano; Augusto F Andrade; Mohan S Nandhu; Julia A Pezuk; Lucas T Bidinotto; Veridiana K Suazo; Luciano Neder; Carlos G Carlotti; Aline P Becker; Luiz Gonzaga Tone; Carlos A Scrideli
Journal:  Mol Neurobiol       Date:  2021-06-03       Impact factor: 5.590

10.  Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.

Authors:  Krishan Kumar; Simon Wigfield; Harriet E Gee; Cecilia M Devlin; Dean Singleton; Ji-Liang Li; Francesca Buffa; Melanie Huffman; Anthony L Sinn; Jayne Silver; Helen Turley; Russell Leek; Adrian L Harris; Mircea Ivan
Journal:  J Mol Med (Berl)       Date:  2013-01-30       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.